JP2008534503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534503A5 JP2008534503A5 JP2008503069A JP2008503069A JP2008534503A5 JP 2008534503 A5 JP2008534503 A5 JP 2008534503A5 JP 2008503069 A JP2008503069 A JP 2008503069A JP 2008503069 A JP2008503069 A JP 2008503069A JP 2008534503 A5 JP2008534503 A5 JP 2008534503A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- use according
- disorder
- clomiphene
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 34
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 16
- 208000035475 disorder Diseases 0.000 claims 16
- GKIRPKYJQBWNGO-QPLCGJKRSA-N zuclomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-QPLCGJKRSA-N 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 9
- 201000003585 eunuchism Diseases 0.000 claims 8
- 208000037106 male hypogonadism Diseases 0.000 claims 8
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 4
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 4
- 230000007423 decrease Effects 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 206010049287 Lipodystrophy acquired Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 230000037182 bone density Effects 0.000 claims 2
- 229960003608 clomifene Drugs 0.000 claims 2
- 208000000509 infertility Diseases 0.000 claims 2
- 230000036512 infertility Effects 0.000 claims 2
- 231100000535 infertility Toxicity 0.000 claims 2
- 208000006132 lipodystrophy Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 229960003604 testosterone Drugs 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 230000036314 physical performance Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000035936 sexual power Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66429005P | 2005-03-22 | 2005-03-22 | |
| US60/664,290 | 2005-03-22 | ||
| PCT/US2006/010022 WO2006102232A2 (en) | 2005-03-22 | 2006-03-17 | Dosing regimes for trans-clomiphene |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246454A Division JP6270281B2 (ja) | 2005-03-22 | 2014-12-05 | トランス−クロミフェン用の投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008534503A JP2008534503A (ja) | 2008-08-28 |
| JP2008534503A5 true JP2008534503A5 (OSRAM) | 2009-03-12 |
| JP5785680B2 JP5785680B2 (ja) | 2015-09-30 |
Family
ID=37024477
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008503069A Expired - Fee Related JP5785680B2 (ja) | 2005-03-22 | 2006-03-17 | トランス−クロミフェン用の投与レジメン |
| JP2014246454A Expired - Fee Related JP6270281B2 (ja) | 2005-03-22 | 2014-12-05 | トランス−クロミフェン用の投与レジメン |
| JP2017221743A Pending JP2018024712A (ja) | 2005-03-22 | 2017-11-17 | トランス−クロミフェン用の投与レジメン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014246454A Expired - Fee Related JP6270281B2 (ja) | 2005-03-22 | 2014-12-05 | トランス−クロミフェン用の投与レジメン |
| JP2017221743A Pending JP2018024712A (ja) | 2005-03-22 | 2017-11-17 | トランス−クロミフェン用の投与レジメン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8247456B2 (OSRAM) |
| EP (2) | EP2392322A3 (OSRAM) |
| JP (3) | JP5785680B2 (OSRAM) |
| KR (1) | KR20070114187A (OSRAM) |
| CN (1) | CN101163467B (OSRAM) |
| AU (1) | AU2006227243B2 (OSRAM) |
| BR (1) | BRPI0609389A2 (OSRAM) |
| CA (2) | CA3071412A1 (OSRAM) |
| MX (1) | MX2007010659A (OSRAM) |
| NZ (1) | NZ560551A (OSRAM) |
| PL (1) | PL383444A1 (OSRAM) |
| RU (1) | RU2413508C2 (OSRAM) |
| WO (1) | WO2006102232A2 (OSRAM) |
| ZA (1) | ZA200707774B (OSRAM) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7737185B2 (en) | 2001-07-09 | 2010-06-15 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene |
| DK1411916T3 (da) | 2001-07-09 | 2008-12-15 | Repros Therapeutics Inc | Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd |
| JP5785680B2 (ja) | 2005-03-22 | 2015-09-30 | リプロス セラピューティクス インコーポレイテッド | トランス−クロミフェン用の投与レジメン |
| MY148330A (en) | 2006-10-31 | 2013-03-29 | Basf Se | Regulation of a process for producing water-absorbing polymer particles in a heated gas phase |
| CN102940619A (zh) * | 2007-10-16 | 2013-02-27 | 利普生物药剂公司 | 用于治疗代谢综合征的珠氯米芬 |
| TW201500041A (zh) * | 2008-11-07 | 2015-01-01 | Repros Therapeutics Inc | 用於代謝症候群與第２型糖尿病的反式氯米芬 |
| UA113291C2 (xx) | 2011-08-04 | 2017-01-10 | Метаболіти транскломіфену і їх застосування | |
| WO2013020215A1 (en) * | 2011-08-09 | 2013-02-14 | Adams Kenneth W | Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males |
| AU2013221478B2 (en) * | 2012-02-14 | 2017-06-01 | Repros Therapeutics Inc. | Selective estrogen receptor modulators with short half-lives and uses thereof |
| MX2014009322A (es) * | 2012-02-29 | 2014-11-10 | Repros Therapeutics Inc | Terapia de combinacion para el tratamiento de la deficiencia androgenica. |
| ES2701400T3 (es) | 2012-05-31 | 2019-02-22 | Repros Therapeutics Inc | Formulaciones para la administración vaginal de antiprogestinas |
| HK1211852A1 (en) | 2012-11-02 | 2016-06-03 | Repros Therapeutics Inc. | Methods and compositions for treating progesterone-dependent conditions |
| HK1216502A1 (zh) * | 2012-11-02 | 2016-11-18 | Repros Therapeutics Inc. | 用於癌症治療的反式-克羅米芬 |
| CA2914503A1 (en) * | 2013-06-05 | 2014-11-12 | Repros Therapeutics Inc. | Trans-clomiphene and its analogues as agents that increase bone mineral density |
| CN108883083A (zh) * | 2016-02-25 | 2018-11-23 | 艾森潘帕克制药股份有限公司 | 两种氯米芬异构体的口服剂型及使用其治疗继发性腺功能减退症的方法 |
| CA2989364C (en) | 2016-04-22 | 2021-07-20 | F.I.S. - Fabbrica Italiana Sintetici S.P.A. | Process for the preparation of enclomiphene citrate having needle shaped crystal habit. |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4061733A (en) * | 1976-10-15 | 1977-12-06 | Narayan Vishwanath Gunjikar | Veterinary compositions for inducing estrus in animals and method |
| US4729999A (en) * | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| EP0206021B1 (de) | 1985-06-08 | 1988-08-10 | ASTA Pharma AG | Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans |
| US4820736A (en) * | 1987-03-20 | 1989-04-11 | Yale University | Use of clomiphene to predict fertility in a human female |
| GB8926171D0 (en) * | 1989-11-20 | 1990-01-10 | Applied Research Systems | Treatment of infertility |
| JPH04312522A (ja) | 1991-04-08 | 1992-11-04 | Yoshiaki Kawashima | 徐放性錠剤の製造方法 |
| US5681585A (en) * | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5776923A (en) * | 1993-01-19 | 1998-07-07 | Endorecherche, Inc. | Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| AU2638795A (en) | 1994-06-17 | 1996-01-15 | University Of Nebraska Board Of Regents | In situ gel-forming delivery vehicle for bio-affecting substances, and method of use |
| DE4435368A1 (de) * | 1994-09-22 | 1996-03-28 | Schering Ag | Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann |
| US6221399B1 (en) * | 1995-08-17 | 2001-04-24 | Csir | Method of making controlled release particles of complexed polymers |
| US5773031A (en) * | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
| IL120262A (en) * | 1996-02-28 | 2001-01-28 | Pfizer | Droloxifene and derivatives thereof for use in increasing serum testosterone levels |
| DE69730982T2 (de) * | 1996-10-28 | 2005-09-01 | General Mills, Inc., Minneapolis | Einbettung und einkapselung von teilchen zur kontrollierten abgabe |
| NZ500649A (en) * | 1997-04-03 | 2001-05-25 | Guilford Pharm Inc | Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making a biosorbable suture, an orthopedic appliance or bone cement for repairing injuries to bone or connective tissue |
| US6653297B1 (en) * | 1997-07-03 | 2003-11-25 | Medical College Of Hampton Roads | Control of selective estrogen receptor modulators |
| RU2200732C2 (ru) * | 1997-08-12 | 2003-03-20 | Глэксо Вэллкам Инк. | Производные трифенилэтилена, способы лечения и профилактики остеопороза, рака груди и сердечно-сосудистого заболевания |
| US6342250B1 (en) * | 1997-09-25 | 2002-01-29 | Gel-Del Technologies, Inc. | Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices |
| US6413533B1 (en) | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| WO2000005954A1 (en) | 1998-07-30 | 2000-02-10 | Stoller Enterprises, Inc. | Treatment of plants with salicylic acid and organic amines |
| WO2000007996A2 (en) * | 1998-08-07 | 2000-02-17 | Chiron Corporation | Pyrazoles as estrogen receptor modulators |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| WO2000076522A1 (en) * | 1999-06-11 | 2000-12-21 | Watson Pharmaceuticals, Inc. | Administration of non-oral androgenic steroids to women |
| AU6132700A (en) * | 1999-09-30 | 2001-04-05 | Chienna B.V. | Polymers loaded with bioactive agents |
| US6258802B1 (en) * | 1999-10-06 | 2001-07-10 | Medical College Of Hampton Roads | Corticoid therapy |
| US20020004065A1 (en) * | 2000-01-20 | 2002-01-10 | David Kanios | Compositions and methods to effect the release profile in the transdermal administration of active agents |
| US7067557B2 (en) * | 2000-05-26 | 2006-06-27 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| WO2001091744A1 (en) * | 2000-05-26 | 2001-12-06 | Harry Fisch | Methods of treating androgen deficiency in men using selective antiestrogens |
| CN100448487C (zh) * | 2000-08-11 | 2009-01-07 | 惠氏公司 | 治疗雌激素受体阳性癌的方法 |
| US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
| WO2002055020A2 (en) * | 2000-12-11 | 2002-07-18 | Testocreme Llc | Topical testosterone formulations and associated methods |
| WO2003005459A1 (en) * | 2001-07-04 | 2003-01-16 | Nichia Corporation | Nitride semiconductor device |
| US7173064B2 (en) * | 2001-07-09 | 2007-02-06 | Repros Therapeutics Inc. | Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy |
| DK1411916T3 (da) * | 2001-07-09 | 2008-12-15 | Repros Therapeutics Inc | Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd |
| US6645974B2 (en) * | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| AU2002330031B2 (en) * | 2001-09-21 | 2007-07-05 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
| US20060269611A1 (en) * | 2001-11-29 | 2006-11-30 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
| US7105679B2 (en) * | 2001-12-19 | 2006-09-12 | Kanojia Ramesh M | Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators |
| JP4312522B2 (ja) | 2003-06-30 | 2009-08-12 | 株式会社リコー | 現像剤補給方法、現像剤補給装置、及び、画像形成装置 |
| BRPI0513129A (pt) * | 2004-07-14 | 2008-04-29 | Repros Therapeutics Inc | método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo |
| NZ556499A (en) * | 2005-02-04 | 2011-02-25 | Repros Therapeutics Inc | Methods and materials with trans-clomiphene for the treatment of male infertility |
| AU2006213856B2 (en) * | 2005-02-11 | 2011-03-17 | Regeneron Pharmaceuticals, Inc. | Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent |
| JP5785680B2 (ja) | 2005-03-22 | 2015-09-30 | リプロス セラピューティクス インコーポレイテッド | トランス−クロミフェン用の投与レジメン |
| CA2617905A1 (en) | 2005-08-05 | 2007-02-15 | Repros Therapeutics Inc. | Methods and compositions for treating female infertility using clomiphene |
| EP1829534A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome |
| CN102940619A (zh) | 2007-10-16 | 2013-02-27 | 利普生物药剂公司 | 用于治疗代谢综合征的珠氯米芬 |
-
2006
- 2006-03-17 JP JP2008503069A patent/JP5785680B2/ja not_active Expired - Fee Related
- 2006-03-17 EP EP11153365A patent/EP2392322A3/en not_active Withdrawn
- 2006-03-17 RU RU2007138867/15A patent/RU2413508C2/ru active
- 2006-03-17 EP EP06738985A patent/EP1865938A4/en not_active Ceased
- 2006-03-17 WO PCT/US2006/010022 patent/WO2006102232A2/en not_active Ceased
- 2006-03-17 NZ NZ560551A patent/NZ560551A/en not_active IP Right Cessation
- 2006-03-17 CN CN2006800089841A patent/CN101163467B/zh not_active Expired - Fee Related
- 2006-03-17 CA CA3071412A patent/CA3071412A1/en not_active Abandoned
- 2006-03-17 PL PL383444A patent/PL383444A1/pl unknown
- 2006-03-17 US US11/815,542 patent/US8247456B2/en not_active Expired - Fee Related
- 2006-03-17 CA CA002597700A patent/CA2597700A1/en not_active Abandoned
- 2006-03-17 MX MX2007010659A patent/MX2007010659A/es active IP Right Grant
- 2006-03-17 KR KR1020077021707A patent/KR20070114187A/ko not_active Ceased
- 2006-03-17 AU AU2006227243A patent/AU2006227243B2/en not_active Ceased
- 2006-03-17 BR BRPI0609389-2A patent/BRPI0609389A2/pt active Search and Examination
-
2007
- 2007-09-11 ZA ZA200707774A patent/ZA200707774B/xx unknown
-
2012
- 2012-08-20 US US13/590,045 patent/US8519004B2/en not_active Expired - Fee Related
-
2014
- 2014-12-05 JP JP2014246454A patent/JP6270281B2/ja not_active Expired - Fee Related
-
2017
- 2017-11-17 JP JP2017221743A patent/JP2018024712A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008534503A5 (OSRAM) | ||
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| NZ604029A (en) | Methods of treating bladder cancer | |
| IL189546A0 (en) | Therapy for the treatment of disease | |
| SG169233A1 (en) | Pharmaceutical compositions comprising apomorphine for pulmonary inhalation | |
| NZ611628A (en) | Use of laquinimod for reducing fatigue, improving functional status, and improving quality of life in multiple sclerosis patients | |
| MY161593A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
| MX344476B (es) | Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal. | |
| MX2010002392A (es) | Composiciones de brimonidina mejoradas para tratar eritema. | |
| TW200501983A (en) | Uses of anti-insulin-like growth factor I receptor antibodies | |
| JP2010505850A5 (OSRAM) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| NZ595376A (en) | Dental anesthetic comprising tetracaine and a vasoconstrictor for intranasal administration | |
| NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| RU2012124268A (ru) | Бензимидазольные соединения и их применения | |
| NZ591525A (en) | Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin | |
| MX2011011459A (es) | Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos. | |
| MX350195B (es) | Analogos de cistamina para el tratamiento de la enfermedad de parkinson. | |
| RU2007138867A (ru) | Режимы дозирования транс-кломифена | |
| RU2014113334A (ru) | Применение ингибитора ароматазы для лечения гипогонадизма и родственных заболеваний | |
| JP2011500589A5 (OSRAM) | ||
| MX2013003523A (es) | Composicion farmaceutica de dosis baja. | |
| MX2012002161A (es) | El uso de lapatinib o una sal o composición farmacéuticamente aceptable del mismo para el tratamiento de cancer. | |
| WO2007139433A8 (en) | Peptide substance normalizing the metabolism in osseous and cartilaginous tissues, pharmaceutical composition on its base and the method of its application |